Ticker brief
SLS SELLAS LIFE SCIENCES GROUP I
Consumer, Non-cyclical · Pharmaceuticals
last close
$13.21
1 day
-13.1%
14 days
+3.4%
mkt cap
$2.9B
signals 14d
46
authors 14d
21
crowd 14d
-0.4σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 211% rich · 89 pctile own 1y | IV/HV 2.00× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | -0.136 15 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +24.88 elevated | 5-session Δ -1.05 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-07-02 (z=2.4) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-28 · now +0.30 (−1 bearish … +1 bullish)
Who spoke21
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @SuperDuperInvst | C | -0.99 | 15 | +0.64 |
| @PK_Fund | C | +0.11 | 4 | +0.58 |
| @SteveDJacobs | C | -1.22 | 4 | +0.11 |
| @YYDSxjm | B | -0.51 | 3 | +0.68 |
| @ClassicRoy | C | -1.52 | 2 | +0.00 |
| @buzztickr | C | · | 2 | +0.32 |
| @cfaryanoconnell | C | -1.48 | 2 | +0.00 |
| @OracleNYSE | C | -0.08 | 1 | +0.75 |
| @HammerstoneMar3 | C | +0.39 | 1 | +0.00 |
| @KampnerSam | A | +0.20 | 1 | +0.15 |
| @LogicalThesis | A | +2.21 | 1 | -0.65 |
| @aboutheoptions | C | · | 1 | +0.00 |
| @equitydd | C | -2.03 | 1 | +0.30 |
| @Financhle | C | · | 1 | +0.60 |
| @WOLF_TradingX | C | -1.40 | 1 | +0.30 |
| @Brad_E_Schulz | C | · | 1 | +0.40 |
| @Flourish_Venkat | C | +0.83 | 1 | +0.65 |
| @Greatstockpix | C | -0.89 | 1 | +0.00 |
| @BiopharmIQ | B | · | 1 | -0.30 |
| @abc51648039 | C | -1.29 | 1 | +0.35 |
| @FintwitAi | C | +1.14 | 1 | +0.75 |
Recent signals30of 46 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @SuperDuperInvst | +0.30 | Start loading NRXP and do not miss the opportunity. — Explicit forward accumulation call, with SLS cited as a prior analogue. | — | tweet ↗ |
| 2026-08-27 | @SuperDuperInvst | +0.55 | Expects NRXP to rise over time similarly to SLS as SLS approaches its high. | -13.1% | tweet ↗ |
| 2026-08-27 | @FintwitAi | +0.75 | Claims a 105% gain since an earlier AI flag at $7.42 | -13.1% | tweet ↗ |
| 2026-08-25 | @SuperDuperInvst | +0.20 | Buy and hold NRXP below $3.45. — Urges investors to buy and hold NRXP, using a prior SLS opportunity as comparison. | -6.2% | tweet ↗ |
| 2026-08-25 | @PK_Fund | +0.00 | Reports an unverified SLS article was removed after the publisher admitted it was not checked. | -6.2% | tweet ↗ |
| 2026-08-25 | @YYDSxjm | +0.65 | Reports record institutional accumulation, with 304 institutions holding 93.8 million shares. | -6.2% | tweet ↗ |
| 2026-08-24 | @SuperDuperInvst | +0.70 | Cites prior long-term picks that gained over 500% and prior shorts that declined, as evidence for patient investing. | -7.8% | tweet ↗ |
| 2026-08-24 | @ClassicRoy | +0.00 | Identifies options with increasing implied volatility. | -7.8% | tweet ↗ |
| 2026-08-24 | @cfaryanoconnell | +0.00 | Lists options with increasing implied volatility. | -7.8% | tweet ↗ |
| 2026-08-23 | @buzztickr | +0.20 | Mixed market data show bullish call accumulation alongside high short interest and few breakout signals | -14.6% | tweet ↗ |
| 2026-08-23 | @SteveDJacobs | +0.30 | Scanner lists stocks showing strength under several momentum methodologies. | -14.6% | tweet ↗ |
| 2026-08-23 | @abc51648039 | +0.35 | Provides bullish threshold, resistance targets, and support for SLS without entry intent. | -14.6% | tweet ↗ |
| 2026-08-23 | @SteveDJacobs | +0.00 | Publishes the first six names from a 21-stock Minervini Trend Template scan without entry intent. | -14.6% | tweet ↗ |
| 2026-08-22 | @BiopharmIQ | -0.30 | Weekly biotech recap aggregates clinical, AI, pricing and deal catalysts across directly discussed names. | -14.6% | tweet ↗ |
| 2026-08-22 | @Greatstockpix | +0.00 | Publishes an Aug. 24 day-trading watchlist; output is capped at the first six explicitly listed symbols. | -14.6% | tweet ↗ |
| 2026-08-22 | @SuperDuperInvst | +0.75 | Recaps SLS rising from below $1.80 to above $15.50 after an earlier recommendation. | -14.6% | tweet ↗ |
| 2026-08-21 | @Flourish_Venkat | +0.65 | Sets an $18 target, with $28-$30 conditional on a weekly close above $20. | -14.6% | tweet ↗ |
| 2026-08-21 | @Brad_E_Schulz | +0.40 | Reports positive sector performance and names leading stocks gaining at least 5%. | -14.6% | tweet ↗ |
| 2026-08-21 | @WOLF_TradingX | +0.30 | Ranks IQMX, HOOD and SLS as the session's three best-performing stocks. | -14.6% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | +0.80 | Says the author is holding SLS after an 800% rise over nine months. | -14.6% | tweet ↗ |
| 2026-08-21 | @Financhle | +0.60 | Reports $3.16M of aggressive SLS $20 call purchases expiring October 16. | -14.6% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | +0.80 | Recaps SLS near $15 and claims followers later chase prior ideas at much higher prices. | -14.6% | tweet ↗ |
| 2026-08-21 | @equitydd | +0.30 | Lists the morning's top gainers; capped at six tickers. | -14.6% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | +0.55 | Buy and hold NRXP, adding on dips. — Explicitly urges NRXP longs to buy, hold and add on dips, comparing it with SLS. | -14.6% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | +0.45 | Buy NRXP before larger investors discover it. — Urges entry in NRXP based on market size and anticipated FDA approval readiness. | -14.6% | tweet ↗ |
| 2026-08-21 | @SuperDuperInvst | +0.85 | Recaps SLS rising more than 800% from below $1.80 to above $16. | -14.6% | tweet ↗ |
| 2026-08-20 | @SuperDuperInvst | +0.70 | Suggests SLS could experience an MRNA-like positive effect. | -1.4% | tweet ↗ |
| 2026-08-20 | @PK_Fund | +0.75 | Argues positive Phase 3 data could make SELLAS an attractive oncology acquisition target. | -1.4% | tweet ↗ |
| 2026-08-20 | @SteveDJacobs | +0.15 | Minervini Trend Template scan lists 24 qualifying stocks and explains its technical badges. | -1.4% | tweet ↗ |
| 2026-08-19 | @aboutheoptions | +0.00 | Promotes a trade-flash and options time-and-sales scanner for the named stocks without stating direction. | -4.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.